The Takeda Vaccines spinoff floated in an upsized offering that granted its former parent $100m in shares.

US-headquartered vaccine developer HilleVax floated on the Nasdaq Global Select Market on Friday in a $200m initial public offering enabling Takeda, the pharmaceutical firm from which it was spun off, to exit. The company had increased the size of the offering from approximately 10.3 million shares to nearly 11.8 million shares and priced them at…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Robert Lavine

Robert Lavine is special features editor for Global Venturing.